
Gene Expression Profiling and Adjuvant Radiation Decisions in CSCC
Key Takeaways
- Conventional AJCC/BWH staging can both undercall metastatic risk in T1/T2a disease and overcall it in T2b/T3, motivating interest in adjunctive biologic stratifiers.
- A Class 1 result may support less intensive follow-up in selected patients, but low-risk GEP should not override adverse clinicopathologic factors such as perineural invasion.
At a Dermatology Times Case-Based Roundtable event moderated by Gaurav Singh, MD, MPH, clinicians discussed whether 40-GEP results change radiation, imaging, and follow-up in high-risk cutaneous squamous cell carcinoma.
Gaurav Singh, MD, MPH, recently led a
Where Traditional CSCC Staging Falls Short
Singh reviewed National Comprehensive Cancer Network (NCCN) risk groups alongside American Joint Committee on Cancer (AJCC) and Brigham and Women’s Hospital (BWH) staging. A meta-analysis on the slides found about 30% of patients with metastatic outcomes were initially staged T1 or T2a, while roughly 75% of T2b and T3 tumors never metastasized.1 Attendees named location, size, immunosuppression, and differentiation as their usual risk criteria.
One attendee added perineural invasion, noting Mohs sections can miss it. “Whether or not you catch the perineural invasion depends on your sections,” the attendee said.
A BWH T2a Cheek Tumor With a Class 1 Result
The first patient was a 69-year-old man with a moderately differentiated tumor measuring 2.2 × 1.8 cm and 3 mm deep, cleared in 3 Mohs stages. His Class 1 result led his surgeon to skip imaging and radiation and examine him every 6 months instead of every 3 months.
Attendees questioned whether the test belonged in this case at all. “I don’t think there’s any data to support that a [GEP] test will change your management for any of these patients,” an attendee said. Another countered, “Medicine’s not always guidelines.”
Not every attendee had the same view. One had ordered the test once, for an immunosuppressed patient with a rapidly growing ear tumor, and found the Class 2A result useful in counseling the patient reluctant to consider radiation. Another saw the value of the test in immunosuppressed patients, whose risk is harder to predict.
Singh noted the NCCN squamous cell guidelines do not currently address gene expression profiling. He also said a low-risk result alongside high-risk traditional features does not justify de-escalation, a point one attendee echoed. “A low-risk GEP is not going to make me relax about any of the perineural invasion,” the attendee said.
Radiation Decisions in an 83-Year-Old With a Lower-Leg Tumor
The second patient had a 3.3 × 2.9-cm moderately differentiated tumor within subcutaneous fat, cleared in 2 stages, and a Class 2A result. Singh cited a 420-patient validation cohort in which the Class 2B metastasis rate reached 52% and the Class 2A rate was 20%.2
Attendees focused on treatment burden. One said adjuvant radiation primarily prevents local recurrence and saw no role here.
“The skin there is just not gonna heal,” an attendee said of the lower leg. Another raised the need for a caregiver to drive the patient to frequent radiation visits. The patient and care team chose clinical and nodal examinations every 3 months.
In a poll, 43.3% of respondents ranked tumor size, depth, and location as the strongest influence on sentinel lymph node biopsy or radiation decisions, followed by patient preference at 23.3% and the GEP result at 13.3%. Class 2A results drew frustration. “Personally, that would be the most frustrating result,” an attendee said.
Singh said stage and profile class can be combined. “Depending on the stage, one can combine the stage with the gene expression profile result to give a more accurate risk of metastasis,” he said.
A Class 2B Result and Adjuvant Radiation in a 55-Year-Old
The third patient, a 55-year-old man, had a 2.4-cm temple tumor invading the temporalis fascia, staged BWH T2b and AJCC T3, and a Class 2B result. Contrast-enhanced MRI and nodal ultrasound showed no disease. He chose nodal ultrasound surveillance over sentinel lymph node biopsy, completed adjuvant radiation, and returned every 2 to 3 months.
Singh presented data showing Class 2B patients treated with adjuvant radiation had about 50% lower median 5-year progression than untreated Class 2B patients, a difference not seen in Class 1 or 2A.3 An attendee noted the study was retrospective and enriched for high-risk patients. Singh agreed the cohort was high risk.
Several attendees said staging alone would prompt a radiation oncology referral. Others saw the result as added support for the patient conversation. “If we have data, we have to do something about it,” Singh said.
Guideline Inclusion Remains the Sticking Point
In the final poll, 68.2% of respondents said NCCN or American Academy of Dermatology guideline inclusion would help them use GEP testing with more confidence. Singh noted Breslow depth also took years to enter staging. Final remarks called for caution and for more evidence.
References
- Farberg AS, Fitzgerald AL, Ibrahim SF, et al. Current methods and caveats to risk factor assessment in cutaneous squamous cell carcinoma (cSCC): a narrative review. Dermatol Ther (Heidelb). 2022;12(2):267-284. doi:10.1007/s13555-021-00673-y
- Ibrahim SF, Kasprzak JM, Hall MA, et al. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test. Future Oncol. 2022;18(7):833-847. doi:10.2217/fon-2021-1277
- Arron ST, Cañueto J, Siegel J, et al. Association of a 40-gene expression profile with risk of metastatic disease progression of cutaneous squamous cell carcinoma and specification of benefit of adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2024;120(3):760-771. doi:10.1016/j.ijrobp.2024.05.022
Related to this article








